Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies
August 1, 2024 3:59 PM EDTJefferies analyst Glen Santangelo lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $30.00 (from $36.00) while maintaining a Buy rating.
The analyst comments "Updating model to reflect 2Q results. Overall, we think NT results remain overshadowed by the pending court ruling... More
Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance
July 30, 2024 5:26 PM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.89, $0.20 better than the analyst estimate of $0.69. Revenue for the quarter came in at $178 million versus the consensus estimate of $173.52 million.
GUIDANCE:
Pacira Pharma sees FY2024 revenue of $680-705 million, versus the consensus of... More
